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2Abstract
Objective. The second version of The Bethesda System for Reporting Thyroid Cytopathology 
endorsed the introduction of non-invasive follicular thyroid neoplasms with papillary-like nuclear 
features (NIFTP) as a distinct entity with low malignant potential into clinical practice. 
Consequently, the risk of malignancy (ROM) of cytological diagnoses has changed, but the 
magnitude of the change remains uncertain. The present systematic review was undertaken to 
obtain more robust information about the true impact of NIFTP on the ROM among patients 
undergoing surgery following a fine-needle aspiration cytology (FNAC) diagnosis of suspicious for 
malignancy (Bethesda V) or malignant (Bethesda VI). As they are managed surgically, these two 
diagnostic categories are the primary entities that are clinically impacted by the advent of NIFTP.
Design. Systematic review and meta-analysis.
Methods. A comprehensive literature search of online databases was performed in November 
2018. The search was conducted looking for data of histologically proven NIFTP with preoperative 
FNAC. 
Results. One-hundred-fifty-seven articles were identified and nine were included in the study. 
Overall, there were 13,752 thyroidectomies with a cancer prevalence of 45.7%. When NIFTP was 
considered non-malignant, the pooled risk difference for ROM was 5.5%. Applying meta-analysis, 
the pooled prevalence of NIFTP among nodules with FNAC of Bethesda V or Bethesda VI was 14% 
and 3%, respectively.
Conclusion. This meta-analysis shows that the inclusion of NIFTP leads to a reduction in the 
ROM for the Bethesda V  and Bethesda VI FNAC diagnostic categories by 14% and 3%, 
respectively. Clinicians should be aware of these data to avoid overtreatment. 
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3Introduction 
Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), formerly 
known as the non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-
invasive EFVPTC), represents a controversial entity and a popular topic (1, 2). Interobserver 
variability in the diagnosis of NIFTP, analogous to its EFVPTC counterpart, is expected to be high, 
even among expert thyroid pathologists. Microfollicular structures and, most importantly, 
borderline-atypical nuclear features characteristic of these lesions, are sources of diagnostic 
discrepancies (3, 4, 5). Due to its indolent behavior, NIFTP should be considered as a neoplasm 
with a low risk of relapse (6). Accordingly, these patients can be treated by lobectomy without a 
need for completion thyroidectomy and radioiodine therapy (6, 7, 8). NIFTP can only be 
diagnosed on surgical specimens, and even if its histological and cytological diagnostic criteria 
are refined continuously, NIFTP identification by fine-needle aspiration cytology (FNAC) is 
currently not feasible in a reliable way (9). In fact, as demonstrated in a recent meta-analysis of 
15 studies including 915 NIFTP, these cases may be classified in all diagnostic categories (DC) of 
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC): 3% were diagnosed as 
Nondiagnostic/Unsatisfactory (ND/U), 10% as Benign (B), 30% as Atypia of Undetermined 
Significance or Follicular Lesion of Undetermined Significance (AUS/FLUS), 21% as Follicular 
Neoplasm or Suspicious for a Follicular Neoplasm (FN/SFN), 24% as suspicious for malignancy 
(SM), and 8% as malignant (M) (10). Importantly, only mild heterogeneity between the studies 
was identified (10). These findings highlight that FNAC will not provide a definite diagnosis of 
NIFTP, and that its presence pre-operatively may be considered only as a possibility in the 
differential diagnosis. 
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4Since the introduction of NIFTP, the second edition of TBSRTC considered NIFTP as a non-
malignant tumor; as a consequence, the risk of malignancy (ROM) associated with its six 
diagnostic categories has been revised leading to a variable reduction of the ROM among the 
categories (11). Particularly, the expected ROM associated with TBSRTC DC Bethesda V and VI 
has decreased from 50-75% and 97-99%, to 45-60% and 94-96%, respectively, based on a limited 
number of retrospective studies (11). These changes could have a significant impact on the 
surgical management for these patients, as overtreatment should be avoided. In fact, in both 
FNAC DC, surgical excision of the lesions is recommended with the options of either a lobectomy 
or a thyroidectomy. 
In this context, the focus of this study was to obtain more robust information about the true 
impact of NIFTP on ROM of patients undergoing surgery due to Bethesda V or VI lesions. 
Accordingly, our meta-analysis aimed to estimate 1) the difference in ROM among all surgical 
patients when considering NIFTP as a malignant versus non-malignant entity; and 2) the 
prevalence of NIFTP among patients undergoing thyroid surgery following a FNAC report of 
Bethesda V or VI. 
Material and Methods 
Conduct of review
This present systematic review was conducted according to Prisma guidelines (Supplementary 
Figure 1). 
 
Page 4 of 26Accepted Manuscript published as EJE-19-0223.R1. Accepted for publication: 23-Jul-2019
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 08/07/2019 12:39:27PM
via Centre Hospitalier Universitaire
5Search strategy
A comprehensive literature search was conducted using the online databases of 
Pubmed/MEDLINE and Scopus. The search aimed to find original studies describing the presence 
of NIFTP among thyroidectomized patients in which there was a presurgical FNAC report 
according to TBRSTC. A combination of the terms “non-invasive”, “encapsulated”, “follicular 
variant”, “NIFTP”, “histopathology” and “thyroid cancer” was used. This approach would allow 
identification of a large number of studies that reported histologically proven NIFTP, and which 
contained information on the presurgical cytological assessment. A beginning date limit was not 
used. The search was updated until November 15, 2018, and no language restrictions were used. 
With an attempt to expand the search, references of the retrieved articles were also screened to 
identify additional studies. 
Study selection
As the main inclusion criterion, only original articles reporting NIFTP cases diagnosed 
histologically in a consecutive series of patients undergoing thyroid surgery over a specific study 
period were included. Subsequently, studies in which preoperative FNAC classification according 
to TBSRTC was not used were excluded. In addition, articles with overlapping patient or nodule 
data were excluded, and case reports were not considered. Two researchers (MB, PT) 
independently reviewed titles and abstracts of the retrieved articles, applying the selection 
criteria; then, all authors independently reviewed the full-text of the remaining articles to 
determine their final inclusion. 
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6Data extraction 
For each included study, the following information was extracted independently by two 
investigators (MB, PT) in a piloted form: 1) study data (authors, year and journal of publication, 
country of origin); 2) study period; 3) number of thyroid surgery; 4) number of cancers among 
patients; 5) number of NIFTP diagnosed by histology; 6) number of preoperative FNA reports of 
Bethesda V or VI; 7) number of cancers among nodules with preoperative FNA reports of 
Bethesda V or VI. Data were cross-checked, and any discrepancies were discussed and mutually 
solved. 
Study quality assessment
The risk of bias of included studies was assessed independently by two reviewers (MB, PT) 
through the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for the following 
aspects: patient selection; index test; reference standard; flow and timing. Risk of bias and 
concerns about applicability were rated as low, high and unclear risk. 
Statistical analysis 
A proportion meta-analysis was performed to obtain the pooled rate of histologically proven 
NIFTP among all patients who underwent surgery and within the subgroup of cases with a cancer 
diagnosis. Particularly, a lesion-based analysis was conducted. Data input: they were entered in 
two columns the number of histologically proven NIFTP and the total number of histologies for 
each study. A risk difference (RD) meta-analysis was conducted to evaluate the difference of ROM 
when considering NIFTP as a malignant or non-malignant entity. For statistical pooling of data, 
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7the DerSimonian and Laird method (random-effects model) was used (12). Pooled data are 
presented with 95% confidence intervals (95% CI) and displayed using a forest plot. The I-square 
index was used to quantify the heterogeneity among the studies, and significant heterogeneity 
was defined as an I-square value > 50%. Egger’s test was carried out to evaluate the possible 
presence of a publication bias. A funnel plot was carried out for any results and publication bias 
might be considered when smaller size studies had on average different results with respect to 
the larger ones. Statistical analyses were performed using the StatsDirect statistical software 
(StatsDirect Ltd; Altrincham, UK). 
Results 
Eligible articles 
After exclusion of duplicate publications, the comprehensive computer literature search 
retrieved 157 articles. Of these, 136 were excluded according to the above criteria after review 
of titles and abstracts, and 21 full-text papers were evaluated. Finally, nine articles were included 
for the purposes of this study (Figure 1) (13, 14, 15, 16, 17, 18, 19, 20, 21). One study presented 
a multi-institutional experience; one of the series (from University of Pennsylvania, Philadelphia, 
PA) was excluded due to the risk of overlapping of data with other studies (21).
Qualitative analysis (systematic review) 
The included studies were published by authors from the USA, Asia, or Europe (13, 14, 15, 16, 
17, 18, 19, 20, 21). Overall, 13,752 thyroidectomies were described with a thyroid cancer 
prevalence of 45.7%. The study design of these articles always included a retrospective 
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8examination of thyroid histological samples from consecutive series of thyroidectomies 
performed over a specific time period. Data on the final histological follow-up were clearly 
identified in texts, figures or tables of the studies. This allowed calculation of the ROM 
considering NIFTP as malignant and the ROM considering NIFTP as a non-malignant entity. In 
addition, the prevalence of NIFTP among those lesions with a preoperative FNAC diagnosis of 
Bethesda V or VI were clearly reported in eight of the selected studies (13, 14, 15, 16, 17, 18, 20, 
21). Table 1 details the main characteristics and findings of the nine included studies. The overall 
distribution of NIFTP according to TBRSTC was similar to that observed in a recent meta-analysis 
with the following percentages in the various diagnostic categories: Bethesda I 3.4%, Bethesda II 
11.2%, Bethesda III 30.9%, Bethesda IV 23.7%, Bethesda V 22.5%, and Bethesda VI 8.3% (10). 
Quantitative analysis (meta-analysis) 
The overall RD of ROM when considering NIFTP as a non-malignant entity was estimated 
pooling the histological results of all nine included studies (Table 1) (13, 14, 15, 16, 17, 18, 19, 20, 
21). Among 13,752 patients undergoing thyroid surgery, 696 (5.1%) NIFTP were identified at 
histology. The pooled RD of ROM was of 5.5% (95%CI from 3.2 to 7.8) (Figure 2); then, when 
NIFTP was considered as a non-malignant entity the risk of malignancy decreased by 5.5%. 
As illustrated in Table 1, data of FNAC diagnosis for the overall series of patients undergoing 
surgery was reported in eight articles (as the study by Lastra et al. (19) did not report data about 
Bethesda V and VI) and the overall number of histologically proven NIFTP with preoperative FNAC 
data was 557 (13, 14, 15, 16, 17, 18, 20, 21). In these articles, there were 1,208 nodules with a 
FNAC diagnosis of Bethesda V and another 3,121 with Bethesda VI. Among all 4,329 cases, there 
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9were 185 NIFTP. At meta-analysis, the pooled prevalence of NIFTP among nodules with a 
cytological classification of Bethesda V was 14% (95%CI from 6 to 26) (Figure 3). Also, the pooled 
prevalence of NIFTP among nodules classified as Bethesda VI was 3% (95%CI from 1 to 6) (Figure 
4). 
Study quality assessment
The risk of bias of the studies is shown in Table 2. Overall, a high risk of bias was found 
regarding the standard reference (i.e. histology). This risk of bias is high because the evaluation 
of histological samples was done before the introduction of NIFTP. In fact, to diagnose NIFTP, one 
needs an analysis of the entire capsule and the totality of the nodule content in the histological 
sample, because the examination of the capsule is an essential prerequisite to exclude invasion 
and analysis of the entire lesion is necessary to exclude the presence of any papillary structures 
(22). Moreover, a high risk of bias was detected for the index test (i.e. FNAC). In fact, the design 
of all the included studies comprised a retrospective re-evaluation of cytological specimens of 
lesions evaluated by FNAC before the introduction of NIFTP as a separate entity. Low risk was 
observed in patient selection and flow and timing of the studies.
Discussion 
NIFTP is the designation for a thyroid neoplasm that was recently introduced to replace the 
nomenclature for lesions formerly classified as non-invasive EFVPTC, an entity with an indolent 
and non-aggressive behavior. Following this reclassification, it has been recommended that 
clinical management consisting of lobectomy without completion thyroidectomy and without 
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radioiodine therapy is an adequate and optimal intervention to manage these patients since the 
recurrence rate is less than 1% one to two decades after surgery (6, 22). However, this 
recommendation assumes that we might be able to diagnose NIFTP preoperatively. Yet, a recent 
meta-analysis confirmed what was apparent from the onset, namely that FNAC diagnoses 
associated with NIFTP may be found in all DC of TBSRTC, i.e. from ND/U (Bethesda I) to M 
(Bethesda VI). Thus, the preoperative identification of NIFTP remains an unrealized goal (10).  
Important for clinical practice, it would be useful to know to what extent the introduction of 
NIFTP affects the ROM within the different cytological categories, assuming that this neoplasm is 
classified as non-malignant. This issue was recently addressed in a meta-analysis by Vuong et al. 
which showed for the first time the impact of NIFTP on the ROM in all TBSRTC DC (23).  In addition, 
there should be a particular focus on those patients for whom surgery is unequivocally 
recommended, i.e. patients with lesions classified by FNA in the Bethesda V and VI categories, 
and for whom the histologic diagnosis of NIFTP is associated with the risk of overtreatment.  The 
present study was undertaken with a different aim, i.e. to provide more robust information on 
this specific subset of thyroid cases, and the possible implications for clinical practice. 
First, our analysis demonstrates that the ROM of a series of consecutive patients undergoing 
thyroid surgery for all causes decreased by 5% when we considered NIFTP as a non-malignant 
tumor. Secondly, when we evaluated the FNAC cases with a diagnosis of Bethesda V and VI, 
considering NIFTP as non-malignant, we found that the ROM decreased by 14% and 3%, 
respectively. These data are in line with the study by Voung et al. who showed a decrease of ROM 
in these two DC of 16% and 2.2%, respectively (23). The almost similar decrease in the ROM in 
the Bethesda V category (14.2%) was also confirmed recently by the study by Ventura et al. This 
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study was not included in our meta-analysis as published after the period of the search of the 
literature performed for the manuscript and did not included cases in the malignant category 
(24).
The second edition of TBSRTC, taking into account the impact of NIFTP, emphasizes that the 
diagnostic criteria used in the M DC should be more strictly applied, limiting this diagnosis to 
cases with clear-cut cytological features of malignancy. The presence of any papillary structures 
with a nuclear score of 3, three or more nuclear pseudo-inclusions, psammoma bodies, or the 
presence of high-grade features (mitosis, necrosis, solid/trabecular pattern) exclude a NIFTP 
diagnosis and are diagnostic of PTC (2, 25, 26, 27). Such an approach is expected to limit the false 
positive diagnosis due to NIFTP in the Bethesda VI.  Furthermore, it would not significantly alter 
the high ROM for this DC, which was estimated in the present meta-analysis as 3%. However, to 
avoid any possible false negative cytological NIFTP cases in the Bethesda VI, one would expect 
more cases to be classified in the Bethesda V, thus making this category particularly affected by 
the introduction of NIFTP.  The ROM of the Bethesda V was 14% in the present meta-analysis, 
but it is based mostly on retrospectives studies. Cytopathologists are now more conscious about 
the NIFTP entity and the potential consequences for the patient’s management. Therefore, many 
are applying stricter criteria for the cytological diagnosis of PTC. For these reasons, in our opinion, 
an increasing number of cases not fulfilling the criteria for the Bethesda VI (including NIFTP) will 
be moved into the Bethesda V, and this is likely to reduce the ROM in the Bethesda Bethesda V 
to an extent that is even higher than the 14% identified in the analysis presented here. Moreover, 
for the same reason as above, we will expect a further decrease in the ROM also in the 
indeterminate DC, (AUS/FLUS and FN/SFN) that is currently estimated in the meta-analysis by 
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Vuong et al. to be at 32% and 30%, respectively (23). Purely follicular-patterned lesions that have 
papillary-like nuclear features with few nuclear pseudo-inclusions will no longer be classified as 
Bethesda VI. These assumptions are consistent with the findings of Ohori et al. who showed that 
the introduction of an institutional quality assurance policy and applying strict criteria to their 
FNAC diagnosis for PTC (i.e. nuclear grooves and >3 pseudonuclear inclusions), led to a reduction 
in the number of Bethesda VI readings on cytology - hence, avoiding false positive diagnosis – in 
lesions that were ultimately diagnosed as NIFTP by histology (25). Consequently, they were able 
to maintain a high ROM rate in their Bethesda VI (25). Endocrine surgeons should be aware that 
the decrease of 14% in the ROM for the Bethesda V is probably an underestimate. For this reason, 
the management should be adapted and be more conservative in selected low risk cases, e.g. in 
lesions with an absence of worrisome ultrasound features or favorable molecular signatures. In 
this situation, a lobectomy may be the optimal first-line intervention in order to avoid 
overtreatment. Of note, Mito et al. showed that adding an explanatory note to the Bethesda V, 
i.e. that NIFTP is within the differential diagnosis, reduces the number of total thyroidectomies, 
and hence improved clinical management (27). 
Certain limitations and strengths of the present study must be mentioned. First, almost all 
publications included in this review were retrospective studies and the authors reviewed 
histological and cytological samples of NIFTP specifically for their study. Of course, this study 
design could introduce a bias. Ideally, one would evaluate the pooled results of prospective 
studies in which patients are managed according to the FNAC diagnosis. However, the studies 
included in this analysis presented data of patients managed before the introduction of NIFTP as 
a separate entity. Moreover, the difference in clinical practice between some Asian centers 
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(active surveillance for low-risk papillary thyroid carcinomas and watchful waiting for 
indeterminate thyroid cytologies) and the still prevalent Western approach (surgery for all 
Bethesda V and VI cytological diagnosis), and the consequently lower prevalence of NIFTP in 
Asian countries could have contributed to high heterogeneity in the present meta-analysis. 
Second, the histologic diagnosis of NIFTP could be compromised in samples collected before its 
introduction (i.e. retrospective studies), because pathologists may not have considered histologic 
issues related to the central parenchymal portion of the tumors, in addition to reviewing the 
entire capsule to exclude invasion. Third, since a subset of NIFTP can be cytologically classified in 
all cytological DC (10), one can conclude that there was a selection bias in the included studies 
since patients with cytological findings in the Bethesda I or II categories are typically not being 
managed surgically. On the other hand, this bias should be absent in Bethesda V or VI lesions, 
which are the focus of our present study, since patients with the latter lesions are typically 
undergoing surgical resection. 
In conclusion, the present meta-analysis reveals that 5% of the surgically removed nodules are 
classified as NIFTP on histology, resulting in an overall reduction of the ROM. More importantly, 
the prevalence of histologically proven NIFTP among lesions with FNAC of Bethesda V and VI is 
14% and 3%, respectively. Treating clinicians should be aware of these changes to the ROM, 
which, after considering other characteristics, may help individualizing patient management and 
avoiding overtreatment. 
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Figure legends
Figure 1. Flow-chart of search of studies. Full explanation of the terms used for the search is 
reported in the text. 
Figure 2. A. Pooled risk difference (95% CI) of ROM in all 13,752 thyroidectomies when 
considering NIFTP as non-malignant entity rather than malignant. The vertical line at point zero 
of the x axis represents the absence of difference. The result shows that if NIFTP is considered as 
a non-malignant tumor, the ROM is reduced by 5.5% (95% CI from 3 to 7). I2 (inconsistency) was 
78.6% (95% CI = 54.6% to 87.2%). B. As shown in funnel plot, a publication bias might be 
considered. Egger test: P = 0.067.
Figure 3. A. Pooled prevalence (95% CI) of NIFTP cases among those 1,208 nodules with a 
preoperative FNAC report of Bethesda V. The results show that NIFTP represents 14% (95% CI 
from 6 to 26) of all cases. I2 (inconsistency) was 95.8% (95% CI = 94.2% to 96.8%). B. As shown in 
funnel plot, a publication bias might be considered. Egger test: P = 0.004.
Figure 4. A. Pooled prevalence (95% CI) of NIFTP cases among 3,121 nodules with a 
preoperative FNAC report of Bethesda VI. The results show that NIFTP represents 3% (95% CI 
from 1 to 6) of all cases. I2 (inconsistency) was 92.7% (95% CI = 88.6% to 94.9%). B. As shown in 
funnel plot, a publication bias might be considered. Egger test: P = 0.004.
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 Figure 1. Flow-chart of search of studies. Full explanation of the terms used for the search is reported in the 
text. 
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 Figure 2. A. Pooled risk difference (95% CI) of ROM in all 13,752 thyroidectomies when considering NIFTP as 
non-malignant entity rather than malignant. The vertical line at point zero of the x axis represents the 
absence of difference. The result shows that if NIFTP is considered as a non-malignant tumor, the ROM is 
reduced by 5.5% (95% CI from 3 to 7). I2 (inconsistency) was 78.6% (95% CI = 54.6% to 87.2%). B. As 
shown in funnel plot, a publication bias might be considered. Egger test: P = 0.067. 
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 Figure 3. A. Pooled prevalence (95% CI) of NIFTP cases among those 1,208 nodules with a preoperative 
FNAC report of Bethesda V. The results show that NIFTP represents 14% (95% CI from 6 to 26) of all cases. 
I2 (inconsistency) was 95.8% (95% CI = 94.2% to 96.8%). B. As shown in funnel plot, a publication bias 
might be considered. Egger test: P = 0.004. 
1196x448mm (120 x 120 DPI) 
Page 21 of 26 Accepted Manuscript published as EJE-19-0223.R1. Accepted for publication: 23-Jul-2019
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 08/07/2019 12:39:27PM
via Centre Hospitalier Universitaire
 Figure 4. A. Pooled prevalence (95% CI) of NIFTP cases among 3,121 nodules with a preoperative FNAC 
report of Bethesda VI. The results show that NIFTP represents 3% (95% CI from 1 to 6) of all cases. I2 
(inconsistency) was 92.7% (95% CI = 88.6% to 94.9%). B. As shown in funnel plot, a publication bias 
might be considered. Egger test: P = 0.004. 
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Bethesda V Bethesda VI
Strickland (2015) 655 85 52.8 39.8 94 156
Canberk (2016) 1886 94 18.1 13.2 69 94
Faquin (2016) 1826 173 48.0 38.5 238 587
Layfield (2017) 312 16 32.6 27.5 29 39
Bychkov (2018) 2,044 59 54.3 51.4 142 695
Kim (2018) 1,891 25 91.2 89.9 393 1038
Lastra (2018) 2,226 139 45.0 38.8 NA NA
Lindeman (2018) 353 26 28.0 20.6 33 99
Zhou (2018) 2559 79 26.4 23.3 210 413
Total 13,752 696 45.7 40.6 1,208 3,121
Legend – Cases reviewed represent all thyroid histological cases reviewed retrospectively in the studies. 
Bethesda V and Bethesda VI column report the overall cases with these FNA among all patients operated upon.
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Table 2. Quality assessment of the studies according to QUADAS-2. 
















Strickland (2015) L H H L L U L
Canberk (2016) L H H L L U L
Faquin (2016) L H H L L U L
Layfield (2017) L H H L L U L
Bychkov (2018) L H H L L U L
Kim (2018) L H H L L U L
Lastra (2018) L H H L L U L
Lindeman (2018) L H H L L U L
Zhou (2018) L H H L L U L
Legend – The risk of bias was defined as low (L), high (H), or unclear (U). 
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Supplementary Table S1 : PRISMA Checklist.
Section/topic # Checklist item Reported on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number. 
2
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known. 3-4
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS). 
NA
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number. 
5
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale. 
5
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched. 
5
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated. 
5
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis). 
6
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators. 
7
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made. 
7
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis. 
7
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 7
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis. 
7
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Supplementary Table S1 : PRISMA Checklist.
Page 1 of 2 
Section/topic # Checklist item Reported on page # 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies). 
7
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified. 
NA
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram. 
8
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations. 
8
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 9
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
8
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 8
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). 8
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). NA
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers). 
10
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias). 
12
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 12
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review. 
1
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097 
For more information, visit: www.prisma-statement.org. 
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